2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study

P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study

Back to course

Pdf Summary

This study, conducted by the Osaka International Cancer Institute in Japan, retrospectively compares various immunotherapy regimens for metastatic non-small cell lung cancer (NSCLC) without driver alterations, using Japanese registry data from 68 cancer care hospitals collected between 2019 and 2021. The aim was to inform regimen selection by assessing overall survival (OS) and time to treatment failure (TTF).<br /><br />The study identified immune-chemo therapy as significantly more effective in improving OS compared to immune-mono therapy for stage IV NSCLC patients eligible for chemotherapy. Among the regimens analyzed, Pembro-chemo therapy notably improved both TTF and OS over ATZ-chemo therapy, though it showed similar results when compared to NIVIPI-chemo therapy. These findings emphasize the importance of well-informed regimen selection but also highlight the need for further research due to the limitations inherent in this study's retrospective nature and reliance on registry data. Factors such as significant differences in baseline patient characteristics, incomplete imaging data, incomplete data on PD-L1 TPS, and a lack of toxicity evaluations were noted.<br /><br />The study underscores the need for prospective trials with standardized criteria for regimen selection to fully validate these findings while pointing to Pembro-chemo therapy as a potentially superior option for this patient group. These insights contribute to the evolving oncology landscape by emphasizing more effective treatment pathways for metastatic NSCLC in real-world clinical practice.

Asset Subtitle

Akito Miyazaki

Meta Tag

Speaker Akito Miyazaki

Topic Metastatic NSCLC – Immunotherapy

Keywords

Osaka International Cancer Institute

immunotherapy regimens

metastatic NSCLC

Japanese registry data

overall survival

time to treatment failure

immune-chemo therapy

Pembro-chemo therapy

retrospective study

prospective trials